

Australia's CSL to invest approximately \$1.5 B in US to manufacture plasma-derived therapies

20 November 2025 | News

Builds on company's more than \$3 billion US investment since 2018 which created thousands of new jobs across 44 states



Global biopharma leader CSL has announced plans to expand its US presence over the next five years, resulting in approximately \$1.5 billion in US capital investments. These investments will generate hundreds of high-quality American jobs, strengthen US manufacturing capabilities of plasma-derived therapies (PDTs), and help secure the US medicine supply chain. .

"The US is the world's leading source for plasma, the main component of plasma derived therapies," said Paul McKenzie, Chief Executive Officer and Managing Director, CSL. "These important medicines are often the most effective or only therapies available for many rare or serious diseases. By expanding our onshore production capacity in the U.S., we are deepening our commitment to patient care, creating high-quality jobs and driving innovation in the US"

These planned investments are subject to approval by CSL's Board of Directors. Since 2018, CSL has invested over \$3 billion into its U.S. operations, creating more than 6,500 new American jobs and bringing our total U.S. headcount to nearly 19,000, representing about 65% of CSL's workforce.

Australia-based CSL provides meaningful career opportunities for Americans nationwide from roles in manufacturing to scientific innovation. CSL's plasma centers serve as an entry point into the healthcare sector, launching new careers and employing thousands of individuals across the country.